ASE Technology Holding Co Ltd vs Novavax Inc — how do they compare? ASE Technology Holding Co Ltd trades at $39.43 (market cap $85.75B), while Novavax Inc trades at $7.92 (market cap $1.31B). The key difference: ASE Technology Holding Co Ltd is far larger — about 65.5× Novavax Inc's market cap, and ASE Technology Holding Co Ltd pays a 1.08% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ASX | NVAX | |
|---|---|---|
Market Cap | $85.75B | $1.31B |
Sector | Technology | Health |
52-Week High | $45.12 | $11.19 |
52-Week Low | $9.63 | $6.22 |
Enterprise Value | $90.15B | $889.30M |
Dividend Yield | 1.08% | — |
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $37.59, up 0.53% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.29, exceeding expectations, and announced a $10.5 billion capital expenditure increase for AI-driven semiconductor demand (Reuters, 2026-07-30). Financials show revenue growth to $645.39 billion in 2025 and a net income margin of 8.46%, though valuation ratios like P/E of 47.78 appear elevated.
Outlook is positive due to AI capacity expansion and robust institutional interest, with 80% analyst buy ratings. Risks include high valuation sensitivity and execution challenges from increased capital spending. The stock's momentum is supported by earnings growth, but investors should monitor margin sustainability amid competitive pressures.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →